A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs TSR 022 (Primary)
- Indications Solid tumours; Tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors TESARO
- 09 Aug 2017 Dose escalation part of this trial has been completed, as per a TESARO Inc. media release.
- 10 Jun 2017 Biomarkers information updated
- 12 May 2017 Planned number of patients changed from 402 to 447.